| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Inflammatory Bowel Diseases | 24 | 2020 | 3209 | 2.76 | Why? |
| Crohn Disease | 17 | 2019 | 959 | 2.41 | Why? |
| Colitis, Ulcerative | 12 | 2019 | 1037 | 2.12 | Why? |
| Biosimilar Pharmaceuticals | 6 | 2019 | 205 | 2.05 | Why? |
| Gastrointestinal Agents | 8 | 2018 | 393 | 1.75 | Why? |
| Infliximab | 9 | 2019 | 502 | 1.24 | Why? |
| Hospital Units | 2 | 2020 | 1017 | 1.02 | Why? |
| Tumor Necrosis Factor-alpha | 10 | 2019 | 2483 | 0.93 | Why? |
| Rectal Fistula | 2 | 2018 | 38 | 0.78 | Why? |
| Standard of Care | 3 | 2020 | 1297 | 0.61 | Why? |
| Janus Kinase Inhibitors | 2 | 2018 | 682 | 0.60 | Why? |
| Quality Assurance, Health Care | 1 | 2020 | 596 | 0.59 | Why? |
| Antibodies, Monoclonal | 8 | 2019 | 8041 | 0.52 | Why? |
| Biological Factors | 1 | 2017 | 276 | 0.51 | Why? |
| Postoperative Care | 1 | 2019 | 755 | 0.50 | Why? |
| General Practitioners | 1 | 2020 | 568 | 0.49 | Why? |
| Patient Care Management | 2 | 2020 | 1514 | 0.47 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.44 | Why? |
| Activities of Daily Living | 1 | 2019 | 1530 | 0.42 | Why? |
| Intestines | 4 | 2019 | 817 | 0.39 | Why? |
| Intestinal Fistula | 2 | 2019 | 43 | 0.38 | Why? |
| Constriction, Pathologic | 5 | 2019 | 212 | 0.35 | Why? |
| Infection Control | 3 | 2020 | 23131 | 0.33 | Why? |
| Immunosuppressive Agents | 4 | 2020 | 6331 | 0.30 | Why? |
| Colitis | 2 | 2019 | 266 | 0.29 | Why? |
| Italy | 14 | 2020 | 38444 | 0.29 | Why? |
| Colonoscopy | 4 | 2018 | 738 | 0.29 | Why? |
| Endoscopy, Gastrointestinal | 3 | 2020 | 1545 | 0.27 | Why? |
| Colon | 2 | 2018 | 669 | 0.24 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 2 | 2020 | 1316 | 0.24 | Why? |
| Integrins | 3 | 2019 | 158 | 0.23 | Why? |
| Practice Patterns, Physicians' | 1 | 2020 | 4927 | 0.22 | Why? |
| Inflammation | 3 | 2020 | 13255 | 0.21 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.21 | Why? |
| Ileitis | 1 | 2019 | 21 | 0.21 | Why? |
| Adalimumab | 3 | 2018 | 389 | 0.20 | Why? |
| Quality of Life | 3 | 2020 | 9820 | 0.20 | Why? |
| Diagnostic Techniques, Digestive System | 1 | 2019 | 29 | 0.20 | Why? |
| Stress, Psychological | 2 | 2019 | 10231 | 0.19 | Why? |
| Interleukin-23 Subunit p19 | 1 | 2018 | 26 | 0.19 | Why? |
| Integrin alpha4 | 1 | 2018 | 21 | 0.18 | Why? |
| Reproductive Behavior | 1 | 2018 | 22 | 0.18 | Why? |
| Fibrosis | 2 | 2019 | 800 | 0.18 | Why? |
| Pneumonia, Viral | 10 | 2020 | 243684 | 0.17 | Why? |
| Drug Substitution | 2 | 2018 | 385 | 0.17 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.17 | Why? |
| Mercaptopurine | 1 | 2017 | 68 | 0.17 | Why? |
| Mesalamine | 1 | 2017 | 89 | 0.17 | Why? |
| Interleukin-23 | 1 | 2017 | 64 | 0.16 | Why? |
| Induction Chemotherapy | 1 | 2017 | 149 | 0.16 | Why? |
| Antibodies, Monoclonal, Humanized | 4 | 2019 | 9335 | 0.16 | Why? |
| Tumor Suppressor Proteins | 1 | 2017 | 165 | 0.16 | Why? |
| Endothelial Progenitor Cells | 1 | 2017 | 103 | 0.16 | Why? |
| Urea | 1 | 2017 | 228 | 0.16 | Why? |
| Membrane Transport Proteins | 1 | 2017 | 152 | 0.15 | Why? |
| Antibodies, Blocking | 1 | 2017 | 174 | 0.15 | Why? |
| Family Relations | 1 | 2019 | 288 | 0.15 | Why? |
| Humans | 49 | 2020 | 930598 | 0.15 | Why? |
| Docosahexaenoic Acids | 1 | 2017 | 145 | 0.15 | Why? |
| Muscle Weakness | 1 | 2019 | 406 | 0.15 | Why? |
| Digestive System Surgical Procedures | 2 | 2019 | 677 | 0.14 | Why? |
| Drainage | 1 | 2018 | 414 | 0.14 | Why? |
| Ustekinumab | 1 | 2017 | 216 | 0.14 | Why? |
| Helicobacter Infections | 1 | 2017 | 216 | 0.14 | Why? |
| Depression | 1 | 2019 | 14116 | 0.14 | Why? |
| Anti-Inflammatory Agents | 3 | 2020 | 6153 | 0.14 | Why? |
| Multimodal Imaging | 1 | 2019 | 534 | 0.14 | Why? |
| Helicobacter pylori | 1 | 2017 | 262 | 0.14 | Why? |
| Telemedicine | 3 | 2020 | 25032 | 0.14 | Why? |
| Endothelium | 1 | 2018 | 460 | 0.14 | Why? |
| Breath Tests | 1 | 2017 | 338 | 0.14 | Why? |
| Wound Healing | 1 | 2018 | 424 | 0.14 | Why? |
| Pandemics | 11 | 2020 | 389249 | 0.13 | Why? |
| Follow-Up Studies | 4 | 2020 | 17020 | 0.13 | Why? |
| Anxiety | 1 | 2019 | 17311 | 0.13 | Why? |
| Nutritional Support | 1 | 2017 | 447 | 0.13 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 3 | 2020 | 9706 | 0.13 | Why? |
| Weight Loss | 1 | 2019 | 826 | 0.12 | Why? |
| Abdominal Pain | 1 | 2019 | 858 | 0.12 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.12 | Why? |
| Risk Reduction Behavior | 1 | 2020 | 946 | 0.12 | Why? |
| Surveys and Questionnaires | 5 | 2020 | 43792 | 0.12 | Why? |
| Adult | 16 | 2020 | 244371 | 0.12 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.12 | Why? |
| Ultrasonography | 2 | 2018 | 4409 | 0.12 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.12 | Why? |
| Treatment Outcome | 7 | 2020 | 51732 | 0.11 | Why? |
| Th17 Cells | 1 | 2017 | 657 | 0.11 | Why? |
| Prospective Studies | 5 | 2020 | 43301 | 0.11 | Why? |
| Middle Aged | 15 | 2020 | 270681 | 0.11 | Why? |
| Aftercare | 1 | 2020 | 1637 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.11 | Why? |
| Young Adult | 8 | 2020 | 93724 | 0.11 | Why? |
| Patient Preference | 1 | 2018 | 750 | 0.11 | Why? |
| Nurse's Role | 1 | 2019 | 614 | 0.10 | Why? |
| Adolescent | 7 | 2020 | 86841 | 0.10 | Why? |
| Patient Education as Topic | 1 | 2020 | 1476 | 0.10 | Why? |
| Remission Induction | 3 | 2018 | 950 | 0.10 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.10 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2017 | 1454 | 0.10 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 1261 | 0.10 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.10 | Why? |
| Physician's Role | 1 | 2019 | 853 | 0.10 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.10 | Why? |
| Lung Diseases, Interstitial | 1 | 2020 | 1476 | 0.09 | Why? |
| Adaptive Immunity | 2 | 2018 | 2585 | 0.09 | Why? |
| Female | 17 | 2020 | 380317 | 0.09 | Why? |
| Male | 16 | 2020 | 367725 | 0.09 | Why? |
| Sexual Behavior | 1 | 2018 | 1322 | 0.09 | Why? |
| Workload | 1 | 2019 | 1887 | 0.09 | Why? |
| Fatigue | 1 | 2019 | 2479 | 0.09 | Why? |
| Eye Diseases | 1 | 2019 | 1150 | 0.09 | Why? |
| Perception | 1 | 2019 | 2827 | 0.08 | Why? |
| Precision Medicine | 1 | 2018 | 1477 | 0.08 | Why? |
| Sleep Wake Disorders | 1 | 2019 | 1463 | 0.08 | Why? |
| Nutritional Status | 1 | 2017 | 1403 | 0.08 | Why? |
| Severity of Illness Index | 6 | 2019 | 48226 | 0.08 | Why? |
| Autoimmune Diseases | 1 | 2020 | 1996 | 0.08 | Why? |
| Emotions | 1 | 2019 | 2418 | 0.08 | Why? |
| Cross Reactions | 1 | 2018 | 4374 | 0.08 | Why? |
| Aged | 9 | 2020 | 215776 | 0.08 | Why? |
| Lymphocytes | 1 | 2019 | 3056 | 0.08 | Why? |
| Health Services Accessibility | 2 | 2020 | 10697 | 0.07 | Why? |
| Remote Consultation | 1 | 2020 | 2396 | 0.07 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.07 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.07 | Why? |
| Diet | 1 | 2017 | 2052 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.07 | Why? |
| Magnetic Resonance Imaging | 2 | 2018 | 6551 | 0.07 | Why? |
| Patient Care Team | 1 | 2019 | 3556 | 0.07 | Why? |
| Immunotherapy | 1 | 2018 | 2421 | 0.07 | Why? |
| Retrospective Studies | 7 | 2019 | 105322 | 0.06 | Why? |
| Referral and Consultation | 1 | 2019 | 4816 | 0.06 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.06 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.06 | Why? |
| Patient Acuity | 2 | 2020 | 1755 | 0.06 | Why? |
| Registries | 2 | 2020 | 12327 | 0.06 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.06 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.06 | Why? |
| Surgical Procedures, Operative | 1 | 2017 | 2662 | 0.05 | Why? |
| Late Onset Disorders | 1 | 2019 | 30 | 0.05 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.05 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.05 | Why? |
| Mucoproteins | 1 | 2018 | 32 | 0.05 | Why? |
| Abdominal Abscess | 1 | 2018 | 41 | 0.05 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.05 | Why? |
| Prognosis | 2 | 2019 | 32490 | 0.05 | Why? |
| Epoxy Compounds | 1 | 2017 | 21 | 0.04 | Why? |
| Sexual Dysfunctions, Psychological | 1 | 2018 | 37 | 0.04 | Why? |
| Dextran Sulfate | 1 | 2017 | 54 | 0.04 | Why? |
| Comparative Effectiveness Research | 1 | 2018 | 178 | 0.04 | Why? |
| Oxylipins | 1 | 2017 | 29 | 0.04 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.04 | Why? |
| Carbon Isotopes | 1 | 2017 | 141 | 0.04 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.04 | Why? |
| Drug Approval | 2 | 2019 | 1325 | 0.04 | Why? |
| Tablets | 1 | 2017 | 219 | 0.04 | Why? |
| Symporters | 1 | 2017 | 80 | 0.04 | Why? |
| Sexual Dysfunction, Physiological | 1 | 2018 | 89 | 0.04 | Why? |
| Clinical Trials, Phase I as Topic | 1 | 2018 | 242 | 0.04 | Why? |
| Mice, Nude | 1 | 2017 | 340 | 0.04 | Why? |
| Polypharmacy | 1 | 2019 | 347 | 0.04 | Why? |
| Cytochrome P-450 Enzyme System | 1 | 2017 | 144 | 0.04 | Why? |
| Interleukin-12 | 1 | 2017 | 156 | 0.04 | Why? |
| Signal Transduction | 3 | 2017 | 7207 | 0.04 | Why? |
| Attitude of Health Personnel | 1 | 2014 | 4741 | 0.04 | Why? |
| Symptom Assessment | 2 | 2020 | 4967 | 0.04 | Why? |
| International Cooperation | 2 | 2019 | 3436 | 0.04 | Why? |
| Cell Adhesion Molecules | 1 | 2018 | 472 | 0.04 | Why? |
| Cell Movement | 1 | 2019 | 695 | 0.04 | Why? |
| Postoperative Period | 1 | 2017 | 651 | 0.04 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.04 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.04 | Why? |
| Enteral Nutrition | 1 | 2017 | 320 | 0.03 | Why? |
| Proportional Hazards Models | 2 | 2017 | 6543 | 0.03 | Why? |
| Clinical Trials as Topic | 3 | 2019 | 7330 | 0.03 | Why? |
| Transfection | 1 | 2017 | 864 | 0.03 | Why? |
| Cross-Over Studies | 1 | 2017 | 867 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2019 | 15421 | 0.03 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.03 | Why? |
| Colectomy | 1 | 2017 | 327 | 0.03 | Why? |
| Glucocorticoids | 2 | 2020 | 4431 | 0.03 | Why? |
| Endoscopy, Digestive System | 1 | 2018 | 352 | 0.03 | Why? |
| France | 2 | 2020 | 12074 | 0.03 | Why? |
| Abdomen | 1 | 2017 | 424 | 0.03 | Why? |
| Nutrition Assessment | 1 | 2017 | 527 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Infertility, Male | 1 | 2018 | 322 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Immunoglobulins | 1 | 2018 | 811 | 0.03 | Why? |
| Child | 2 | 2019 | 70012 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 8811 | 0.03 | Why? |
| Animals | 5 | 2018 | 78931 | 0.03 | Why? |
| Diagnostic Imaging | 1 | 2019 | 1044 | 0.03 | Why? |
| Critical Pathways | 1 | 2020 | 1587 | 0.03 | Why? |
| Lung Transplantation | 1 | 2020 | 1554 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2019 | 1956 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2019 | 3788 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2020 | 3129 | 0.02 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Drug Design | 1 | 2018 | 2627 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Decision Making | 1 | 2020 | 3132 | 0.02 | Why? |
| Colorectal Neoplasms | 1 | 2019 | 1884 | 0.02 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2018 | 3803 | 0.02 | Why? |
| Health Care Surveys | 1 | 2014 | 2942 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Patient Safety | 1 | 2018 | 4885 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Immunologic Factors | 1 | 2019 | 4206 | 0.02 | Why? |
| Gastroenterology | 1 | 2014 | 1352 | 0.02 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.01 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Emergency Medical Services | 1 | 2019 | 3557 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Europe | 1 | 2014 | 12702 | 0.01 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.01 | Why? |
| Biomarkers | 1 | 2019 | 23361 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |